Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis

NCT ID: NCT06328075

Last Updated: 2024-03-25

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 15000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-01-01
• Study Completion Date: 2026-01-01

Brief Summary

The goal of this study is to develop an algorithm using artificial intelligence (AI) to assist identification of potential ATTR-CM cases using routine transthoracic echocardiography.

The main questions it aims to answer are:

• is the algorithm able to diagnose ATTR-CM
• is the algorithm able to diagnose different types of ATTR-CM (ATTRv, ATTRwt)

This is a non interventional study. Participant' echocardiographies will be, after deidentification, used to train, valid and test the algorithm.

Detailed Description

Transthyretin (TTR) amyloidosis is a serious systemic disease affecting multiple target organs including the peripheral nervous system, heart, and kidney. In the absence of treatment, the median survival for symptomatic forms with cardiac involvement is 3 to 4 years.

In recent years, new treatments have proven their effectiveness in transthyretin amyloidosis, making it possible to slow the progression of neuropathy and cardiac damage. These treatments seem particularly effective when they are initiated at an early stage of the disease.

It is therefore necessary to establish the diagnosis as early as possible in order to benefit the most from the treatment. However, during the clinical examination, the electrocardiogram or the routine echocardiography, the signs evoking cardiac amyloidosis are not specific. The initial diagnosis is therefore often difficult, missed or delayed and the median time between the first symptoms and the initiation of treatment is approximately 3 years.

It is therefore the initial phase of diagnosis that must be improved in a sufficiently sensitive and specific manner to detect potential cases early while avoiding unnecessary examinations in the event of a low probability.

The objective of the study is to develop and validate a tool to assist the screening of cardiac transthyretin amyloidosis, from standard echocardiography, without the need for active participation of the cardiologist in the diagnostic process. This diagnostic contribution will allow the cardiologist to evoke the diagnosis of cardiac amyloidosis and to consider additional explorations.

Conditions

Amyloid Cardiomyopathy; Transthyretin Amyloid Cardiomyopathy; Transthyretin Cardiac Amyloidosis

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: OTHER

Study Groups

Transthyretin cardiac amyloidosis (ATTR-CM)

Patients with an ATTR-CM and undergoing a transthoracic echocardiography

non interventional study

Intervention Type: OTHER

non interventional study

Controls

Patients without cardiac amyloidosis undergoing transthoracic echocardiography as part of cardiological follow-up

non interventional study

Intervention Type: OTHER

non interventional study

Interventions

non interventional study

non interventional study

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Cardiac transthyretin amyloidosis diagnosed on the classic criteria:

1. Absence of monoclonal immunoglobulin AND

2. Presence of a bisphosphonate scintigraphy with enhancement in the cardiac area OR

2-Presence of a cardiac biopsy showing transthyretin (Congo red positive) cardiac amyloidosis (demonstrated either by immunostaining or by mass spectrometry) OR 3-Presence of a peripheral biopsy showing transthyretin amyloidosis (see above) associated with cardiac infiltration (parietal thickness >12mm without other cause of cardiac hypertrophy)

• No opposition to research

• Another cause of cardiac amyloidosis: AL AA amyloidosis…
• Mixed heart disease with associated presence of non-amyloid heart disease (ischemic heart disease, dilated, etc.)

Control patients:

• Indication for transthoracic echocardiography as part of cardiological follow-up
• Patient affiliated with social security
• Patient's agreement to participate in the research and signature of the consent form.
• Technical conditions of the examination and echogenicity allowing acquisition of good quality echocardiographic images, allowing post processing

• Presence of cardiac amyloidosis as defined above
• Presence of transthyretin amyloidosis even without demonstrated cardiac involvement
• Patient monitored for asymptomatic transthyretin mutation
• Minor patient or patient unable to give their consent (unconscious patient, under guardianship)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bichat Hospital

OTHER

Sponsor Role: collaborator

Bioquantis

UNKNOWN

Sponsor Role: collaborator

Algalarrondo Vincent

OTHER

Sponsor Role: lead

Responsible Party

Algalarrondo Vincent

Principal Investigator, Director of the referral center CRMR -CERAMIC CARDIO

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Gabriel Steg, MD, PhD

Role: STUDY_CHAIR

Bichat Hospital

Locations

Bichat

Paris, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Vincent Algalarrondo, MD, PhD

Role: CONTACT

vincent.algalarrondo@aphp.fr

+33140257785

Gregory Ducrocq, MD, PhD

Role: CONTACT

gregory.ducrocq@aphp.fr

+33140256600

Facility Contacts

Vincent Algalarrondo, MD, PhD

Role: primary

vincent.algalarrondo@aphp.fr

+33140257785

Gregory Ducrocq, PD, PhD

Role: backup

gregory.ducrocq@aphp.fr

Other Identifiers

20211029191554

Identifier Type: OTHER

Identifier Source: secondary_id

AI-ATTR-ECHO

Identifier Type: -

Identifier Source: org_study_id